SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-19-006670
Filing Date
2019-05-09
Accepted
2019-05-09 16:06:22
Documents
44
Period of Report
2019-03-31

Document Format Files

Seq Description Document Type Size
1 form10-q.htm 10-Q 480055
2 ex31-1.htm EX-31.1 17674
3 ex32-1.htm EX-32.1 6640
  Complete submission text file 0001493152-19-006670.txt   2527495

Data Files

Seq Description Document Type Size
4 XBRL INSTANCE FILE lixt-20190331.xml EX-101.INS 350435
5 XBRL SCHEMA FILE lixt-20190331.xsd EX-101.SCH 42574
6 XBRL CALCULATION FILE lixt-20190331_cal.xml EX-101.CAL 25616
7 XBRL DEFINITION FILE lixt-20190331_def.xml EX-101.DEF 144048
8 XBRL LABEL FILE lixt-20190331_lab.xml EX-101.LAB 263698
9 XBRL PRESENTATION FILE lixt-20190331_pre.xml EX-101.PRE 183406
Mailing Address 248 ROUTE 25A NO. 2 EAST SETAUKET NY 11733
Business Address 248 ROUTE 25A NO. 2 EAST SETAUKET NY 11733 310 203 2902
LIXTE BIOTECHNOLOGY HOLDINGS, INC. (Filer) CIK: 0001335105 (see all company filings)

IRS No.: 202903526 | State of Incorp.: DE
Type: 10-Q | Act: 34 | File No.: 000-51476 | Film No.: 19810503
SIC: 2834 Pharmaceutical Preparations